Biomarker Twitter Feed

See what's happening across the Internet in biomarker development.


View on Twitter!

Prevention of Organ Failure Centre of Excellence

The PROOF (Prevention of Organ Failure) Centre is a not-for-profit organization that develops and implements blood-based biomarker tests to better manage patients with heart, lung and kidney failure and prevent disease progression. By embracing a cross-disciplinary team of people and uniting organizations including commercial partners, we can speed up the development of these tests, applying them sooner to improve and save lives.

We are hiring!

January 16, 2012

The PROOF Centre is looking for a Business Consultant to join it’s team. Click here to view a…

Genes, machines and stems cells make a lively public forum!

January 3, 2012

At a public forum hosted by the Transplant Research Foundation of BC on November 30, 2011, Dr. Bruce McManus spoke…

Blood tests instead of biopsies to detect or predict rejection of organ transplants

November 17, 2011

Read what Dr. Bruce McManus has to say on blood tests that can detect acute and chronic rejection of organ transplants…

Glimpsing into a brighter future: The fourth annual heart transplant patient education day

November 16, 2011

How will PROOF contribute to a brighter future for heart transplant patients? Find out in the November 2011

More News

February 5-7, 2012

AllerGen Seventh Annual Research Conference: Innovation from Cell to Society Fairmont Royal York, Toronto, Ontario Dr. Scott Tebbutt, Chief Scientific…

November 30, 2011

Personalized Healthcare – a Sustainability Solution? The capacity to make care more particular and specific to each person…

November 30, 2011

Applications for Affymetrix® Microarrays 12:00pm to 2:00pm, UBC James Hogg Research Centre at St. Paul’s Hospital, Vancouver, BC.…

More Events

Why work with us?

As a not-for-profit organization, we can provide flexible partnering opportunities.
We can provide multiple potential points of collaboration with a focus on critical clinical needs and opportunities through strategic engagement of industry, academia, government, and clinician stakeholders.
We have an agnostic approach to technology platforms, allowing multiple and best in class choices.

We provide single-point access to cohorts, technology platforms and renowned experts in all facets of heart, lung and kidney failure.